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Phone : 33 1 44 49 30 66 Fax : 33 1 45 67 19 30 
Abstract  
 
Glanzmann thrombasthenia (GT) is an autosomal recessive inherited bleeding disorder 
characterized by an impaired platelet aggregation due to defects in integrin αIIbβ3 (ITGA2B, 
ITGB3), a fibrinogen receptor. Mutations from 24 GT patients and 2 carriers of various 
origins, Caucasian, North-African and Asian were characterized. Promoter and exon 
sequences of αIIb and β3 genes were amplified and directly sequenced. Among 29 identified 
mutations, 17 new allelic variants resulting from nonsense, missense and deletion / insertion 
mutations were described. RNA alterations were evaluated by using web-servers. The αIIb 
p.S926L, p.V903F, and β3 p.C38Y, p.M118R, p.G221D substitutions prevented complex 
expression at the surface of Cos-7 cells by altering the αIIb or the β3 subunit structure. As 
shown by free energy analyses applied on the resolved structure of αIIbβ3 and structural 
modeling of the mutant, the p.K253M substitution of β3 helped to define a key role of the 
K253 in the interaction of the αIIb β-propeller and the β3 β-I domains. Finally, the αIIb 
p.Q595H substitution allowed cell surface expression of the complex but its corresponding 
c.2800G>T mutation is predicted to alter normal RNA splicing. Characterization of GT 
mutations is of interest for prenatal diagnosis, genetic counseling and provides useful tools for 
structure-function relationship studies of αIIbβ3. 
 
 
Keywords 
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INTRODUCTION 
Glanzmann thrombasthenia (GT) is an autosomal recessive bleeding disorder characterized 
by a prolonged bleeding time and an impaired platelet aggregation in response to 
physiological agonists such as ADP, thrombin, collagen and epinephrine [Caen, 1972]. GT 
results from quantitative and / or qualitative defects of the fibrinogen (Fg) platelet receptor, 
the glycoprotein αIIbβ3 complex (OMIM accession number #273800). Classically GT has 
been divided into 3 subtypes defined by the αIIbβ3 content of patient’s platelets : Type I, no 
or only trace amounts of αIIbβ3; Type II and variant, respectively with low and near normal 
platelet surface content of functionally impaired αIIbβ3 [Nurden, 2005]. To date, more than 
100 different mutations involved in GT phenotype have been described in the αIIb gene and 
60 in the β3 gene (http://sinaicentral.mssm.edu/intranet/research/glanzmann/menu). The 
nature of GT mutations is highly variable excepting some that are commonly identified in 
consanguineous populations such as the αIIb c.409-3_418del (IVS3-3del13) and the β3 
c.2031_2041del (2031del11) respectively detected in Arab and Iraqi-Jewish GT populations 
[Newman et al., 1991], the αIIb c.1544+1G>A (IVS15+1/G>A) mutation in French Gypsies 
[Schlegel et al., 1995], or the β3 c.1053_1058del (1053CCCAGG) deletion in North-Africans 
[Morel-Kopp et al., 1997].  
Characterization of GT mutations in patients is critical for prenatal diagnosis and genetic 
counseling. We report here the characterization of 29 mutations identified in 24 
thrombasthenic patients and 2 asymptomatic carriers. Using site directed mutagenesis, cell 
expression models, in silico tools and the resolved structure of the αIIbβ3 complex, we have 
analyzed the pathogenic role of 17 newly described allelic variants. Structural modeling 
studies of an allelic variant of GT has revealed the importance of the Lys253 in the interaction 
of the αIIb β-propeller and the β3 β-I domains. 
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MATERIAL AND METHODS 
 
Patients 
Blood samples from patients were sent to our laboratory for confirmation of GT diagnosis 
and genetic analysis. Propositi and their detailed platelet phenotype are listed in Supp Table 
S1. Propositi 4 and 15 are GT carriers. Propositus 4 who had presented mild bleeding and 
healing difficulties during tympanoplasty was addressed to the laboratory for GT investigation 
after flow cytometry analysis revealed a 50 % reduction of αIIbβ3 platelet surface expression. 
Propositus 15 was unexpectedly found to be a GT type I carrier during neonatal alloimmune 
thrombocytopenia diagnosis following in utero fetal death. Her platelets were phenotyped 
HPA-3a negative but genetically HPA-3a/b as determined by PCR-Sequence Specific Primer 
testing (data not shown).  
As shown in Supp Table SI, 19 propositi of 22 of confirmed platelet phenotype  (86 %) 
were found to be of type I (< 5 % of αIIbβ3 and < 25 % of Fg normal platelet contents). Three 
propositi were found to be of type II as their platelets presented low but significant αIIbβ3 
content (≥ 10 %) and a relatively high level of intra-platelet Fg (≥ 50 %). None of these 
patients had been previously studied for molecular gene defects. Patients described herein 
gave their informed consent for genetic analysis. 
 
Monoclonal antibodies 
Monoclonal antibodies (Moab) SZ1 (anti-GPIX), SZ22 (anti-αIIb), SZ21 (anti-β3), P2 
(anti-αIIbβ3) and E3 (anti-Fg) were purchased from Beckmann Coulter-France (Villepinte, 
France). Moabs AP2 (anti-αIIbβ3) and AP3 (anti-β3) were obtained from Lucron Bioproducts 
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5
(Lille, France). Moab Y2-51 (anti-β3) was purchased from DAKO ( Trappes, France). Moab 
XIIF9 to β3 was a generous gift from G.Vezon (CRTS, Bordeaux, France). In some flow 
cytometry experiments, Moabs SZ22, SZ21 and P2 were directly conjugated to FITC.  
 
Blood samples 
Blood samples from patients were collected by venipuncture using 5mM ethylene-diamine-
tetra-acetic acid as an anticoagulant. Platelet were separated by differential centrifugation and 
used or stored in 70% ethanol at –80°C until RNA was extracted. In some cases, 500 µl of 
whole blood were mixed with 1.3 ml of RNA Later (Applied Biosystem, Courtaboeuf, 
France) and were kept frozen at –80°C for subsequent RNA extraction. 
 
Flow cytometry 
For platelet glycoprotein and Fg content analysis, 50 µl of EDTA anticoagulated whole 
blood was diluted in 500 µl of phosphate saline buffer (PBS) pH 7.2 containing 1 % (wt/vol) 
BSA-fraction V (Euromedex, Souffelweyersheim, France) and 3 mM EDTA (PBE buffer). 
Cell were fixed by adding 1.5 ml of PBS - 3 mM EDTA, pH 7.2, containing 1.33 % (vol/vol) 
of a methanol-stabilized formaldehyde solution (Fisher Scientific, Illkirch, France) for 15 min 
at room temperature (RT). The reaction was stopped by adding 2 ml of PBE before cells were 
pelleted by centrifugation at 1500 g for 10 min. Pelleted cells were washed in 2 ml PBE 
before to be resupended in 1 ml PBE containing 0.1 % (wt/vol) sodium azide and store at 4°C 
until use. 40 µl of the fixed cells suspension were incubated with 3 µg/ml Moab in PBE (100 
µl final volume), for 1 h at RT. After two washes in 2 ml PBE, the bound Moabs were 
detected by using a polyclonal goat anti-mouse IgG conjugated to FITC (Jackson 
Immunoresearch Europe, Newmarket, UK) diluted in PBE (1 µl for 10 ml) for 30 min at RT. 
Following one wash in 2 ml PBE, mean fluorescence intensity of cells was analyzed on an 
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XL-MCL Flow cytometer (Beckman Coulter, Villepinte, France). To detect intraplatelet Fg, 
each incubation steps were done in presence of 1% (wt/vol) saponine (Fischer Scientific). 
Amounts of proteins are expressed as a percentage of the mean amounts obtained with normal 
platelets from 10 healthy donors.  
 
To analyze αIIβ3 wild type or mutant complexes expressed at the surface of transfected 
Cos-7 cells, cells were collected by Trypsin-EDTA treatment and washed 2 times in PBS-1% 
(wt/vol) BSA. 5 x 105 cells were incubated in 100 µl PBS containing 3 µg/ml Moabs (SZ22, 
SZ21 or P2) conjugated to FITC for 1 h at RT. Cells were washed twice in 2 ml PBS-BSA 
before to be analyzed by flow cytometry. Dead cells were discarded from analysis by using 
the 7-AAD viability dye (Beckmann-Coulter). Results are expressed as a percentage of 
positive cells for the concerned antigen.  
 
DNA/RNA extractions 
Genomic DNA was isolated from peripheral blood according to a published procedure 
[Jallu et al., 2002] or by using the MagNA Pure Compact Instrument and the Nucleic Acid 
Isolation Kit I (Roche Diagnostics, Meylan, France). In some cases, DNA samples were 
obtained by using QIAamp DNA Blood Mini kit (Qiagen, Courtaboeuf, France). RNA 
extractions were done on platelets by using the Rneasy Protect MiniKit (Qiagen). DNAs and 
RNAs were extracted according to the manufacturers’ instructions. 
 
Sequencing analysis 
Sequencing was performed as previously described [Quintanar et al., 1998] or by 
GenoScreen (Lille, France). Primers defined by Kato and coworkers [Kato et al., 1992] and 
Jin and co-workers [Jin et al., 1993] were respectively used to amplify coding sequences of 
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7
αIIb and β3 genes from genomic DNA. Primers to amplify promoter sequences of αIIb and 
β3 have been respectively defined according to the genes’ reference sequences NG_008331.1 
and NG_008332. αIIb promoter sequences were studied by using the following primer pairs 
(“a” forward, “b” reverse) : 
IIbP1a CGCCAGAATTCTCAGTCACGAAGCTTGGCTCAAGACGGAG 
IIbP1b CCAGCCAGATATCAGCTATGTACTACCACCGTGCTAGTCC 
IIbP2a CGCCAGAATTCTCAGTCACGGGTAAAGATTCAAGAGACAT 
IIbP2b CCAGCCAGATATCAGCTATGTCAGATTCCTCCACAGGAAG 
IIbP3a CGCCAGAATTCTCAGTCACGGAAGGGAAGGAGGAGGAGCT 
IIbP3b CCAGCCAGATATCAGCTATGCTTCCCTTACGGCTCACCTC 
Underlined sequences are non genomic sequence for sequencing PCR products. Promoter 
and exon 1 sequences of β3 gene were amplified with the primer pair 
IIIaE1a ATGTGGTCTTGCCCTCAACAGGTAG 
IIIaE1b CACGCTCTCACCCAGGAAGTTACAG by using the Advantage GC genomic 
PCR kit (Clontech, Saint-Germain-en-Laye, France) and then sequencing was done with the 
forward primer 3aseq-P1a CCGGAAAACCAAACTAAGGC and the reverse primer 3aseq-
P1b GACCAGTCCTCCGCGTTTGC.  
All identified mutations were confirmed by PCR-Restriction Fragment Length 
Polymorphism (PCR-RFLP) analysis on a second PCR product. Restriction enzymes are 
listed in tables 1 and 2 with the corresponding mutations. The experimental details of these 
RFLP assays can be obtained upon request. When the mutation did not introduce restriction 
modification, sequencing was done on a second PCR-product. For nucleotide numbering the 
A nucleotide of the ATG start was designated +1 (cDNA ITGA2B and ITGB3 GenBank 
accession numbers NM_000419.3 and NM_000212.2 respectively). For amino acid 
numbering used in the text, the first amino acids of the mature αIIb and β3 proteins were 
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8
designated +1. Residue numbering according to the Human Genome Variation Society 
(HGVS) nomenclature that designed as +1 the translation initiating methionine 
(http://www.hgvs.org/mutnomen) is also shown in tables 1 and 2. Both numberings differ by 
31 and 26 residues that correspond to the signaling peptides of αIIb and β3 respectively. All 
identified allelic variations have been deposited on the NCBI dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP/) and their corresponding accession numbers are indicated 
in tables 1 and 2. 
 
Site directed mutagenesis and in-vitro expression 
Site directed mutagenesis and in vitro expression in Cos-7 cells were done as previously 
described [Jallu et al., 2002] or by using the QuikChange® II XL Site-Directed Mutagenesis 
Kit (Agilent Technologies, Massy, France) according to the manufacturer’s instructions. In 
some mutagenesis experiments, plasmid pcDNA3.1-Zeo containing the αIIb cDNA was used 
instead of pcDNA3.1-Neo (Invitrogen, Cergy Pontoise, France). 
 
Minigene study 
To study a mutation predicted to affect mRNA splicing, an αIIb gene fragment covering 
exons 17 to 20 and containing the mutation was synthesized and introduced in the plasmid 
Exontrap (Mobitech, Goettingen, Germany). The wild type form of the sequence was obtained 
by site directed mutagenesis. Synthesis, cloning and site directed mutagenesis were done by 
the Epoch Biolabs, Inc. Company (Sugar Land, TX, USA). Following transient transfection in 
Cos cells, total RNA was extracted and mRNA amplified for the exon 17 to 20 and directly 
sequenced.  
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9
Western-blot analysis 
Trypsin-EDTA collected Cos-7 cells were washed 2 times in PBS and 1 time in 50 mM 
Tris-HCL pH 7.6, 150 mM NaCl. Cells were resuspended (1.5 x 107 cells) in 100 µl of the 
same Tris buffer containing 1% (wt/vol) Triton-X 100 and 2 mM para-Methyl Sulfonyl 
Fluoride (PMSF). They were lysed for 30 min at 4°C and the lysate centrifuged at 16.000 g 
for 30 min at 4°C. The supernatant was diluted with 4 volumes of a 150 mM NaCl solution 
containing 2.5 % (wt/vol) Sulfate Dodecyl Sodium (SDS), 31.25 mM n-ethylmaleimide and 
2.5 mM PMSF. The SDS lysate was heated to 100°C for 5 min before 35 µl were used for 
western-blot analysis as previously described [Jallu et al., 1994] with a minor modification : 
bound antibodies were detected by using anti-mouse IgG conjugated to peroxidase associated 
with a chemiluminescence detection technique. 
 
Computational analyses 
The effect of mutations on intron splicing has been predicted in silico by using the 
following tools : Genscan (http://genes.mit.edu/GENSCAN.html [Burge and Karlin, 1998]) 
and NNSPLICE 0.9 (http://www.fruitfly.org/seq_tools/splice.html [Reese et al., 1997]). 
Modifications of the splicing factors binding sites pattern resulting from the mutations were 
evaluated by using the ESEFinder tool [Cartegni et al., 2003; Smith et al., 2006]. 
To compare wild type and a mutant headpiece of αIIbβ3, modeling has been done using 
the structure (PBD code 2VDL) published by Springer et co-workers [Springer et al., 2008]. 
Residues 1-452 of αIIb and 109-352 of β3 were taken into account. The interface between the 
protein chains has a correct resolution (2.75 Å) and the residues implicated at the interface 
have all good normalized B-factor values. A structural model of the mutant has been built. 
This model was checked using ProCheck software to analyze the quality of the modification 
[Laskowski et al., 1993] and the side-chain position was analyzed with SCWRL [Canutescu et 
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10
al., 2003]. Finally, the FastContact web server (http://structure.pitt.edu/servers/fastcontact/) 
was used to estimate the direct electrostatic and desolvation interaction free energy between 
two proteins [Camacho and Zhang, 2005; Champ and Camacho, 2007]. The computational 
estimation of the binding free energy is based on a statistically determined desolvation contact 
potential and Coulomb electrostatics with a distance-dependent dielectric constant [Camacho 
and Zhang, 2005]. This free energy provides a reasonably good estimate of experimental 
binding affinities from complex crystal structures.  
 
RESULTS 
Clinical GT diagnosis was confirmed in our laboratory by immunological or biochemical 
studies (see Supp Table S1). Genomic DNA samples from patients were studied for molecular 
defects in promoter and exon sequences of genes coding for αIIb and β3 by direct sequencing 
of the corresponding PCR products. Allelic variations identified in these genes are reported in 
tables 1 and 2. To avoid erroneous identification due to amplification errors, all sequence 
alterations have been confirmed on a second PCR product either by a PCR-RFLP technique 
when a restriction site modification was observed or by new sequencing analysis in other 
cases. Restriction enzymes that have been used are list d in tables 1 and 2 with their 
corresponding allelic variant. When available, DNAs from patient’s relatives were also 
analyzed and used to confirm the allelic variations (data not shown). 
 
Sequence alterations detected in the αIIb gene 
For 18 propositi, a total of 20 mutations was identified in the gene coding for αIIb (see 
table 1). Five lead to nonsense codons : patients 1, 6, 7, 8 and 17. It should be noted that 
patient 17 was phenotype GT type II because the second mutation that had not been identified 
allowed residual expression of αIIbβ3 (see Supp Table S1). Three mutations directly affect a 
splice site : patients 9 and 12 with a single point mutation and 3 unrelated propositi (GT 
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patients 3 and 5, and the carrier 4) who present the same 13 base pair deletion c.1442-
13_1442-1del. However for these latter propositi, an unknown common ancestry cannot be 
excluded as all are European Caucasians who live in the north-east of France. Two 
heterozygous single base insertions were identified in patient 2. These mutations are predicted 
to result in frame-shift anomalies creating a downstream stop codon and premature 
termination. A 10 base pair deletion identified in patient 14 also leads to a frame shift 
anomaly. Other gene anomalies identified affecting αIIb, were missense mutations. Three of 
them (patients 6, 10, 15 and 16) have not been described so far and 6 (patients 3, 11, 12, 13 
and 18) have already been reported (see references in Table 1). Among the 9 heterozygous 
compounds, 4 second obligatory mutations (patients 5, 7, 17 and 18) remain to be identified 
(NI abbreviation (not identified) in tables).  
 
Sequence alterations detected in the β3 gene 
Ten mutations were identified in the gene coding for the β3 glycoprotein for 8 propositi 
(see Table 2). One single point mutation (patient 20) is responsible for a nonsense codon and 
a second (patient 19) disrupts an acceptor splice site. An homozygous 4 base pair deletion 
located downstream of the donor splice site (c.1125+3_1125+6del) of intron 8 has been 
identified as the unique mutation in patient 25. In patient 26, two silent homozygous 
mutations, c.1143C>A and c.1260G>A (20507C>A and 20624G>A with genomic 
numbering : accession number J05427) located in exon 9 are observed. These mutations have 
been reported to be responsible for type I GT [Jin et al., 1996]. Though silent, their 
association induces exon 9 skipping and the introduction of five intronic bases in the final 
transcript [Jin et al., 1996]. Analysis of the mRNA from patient 26 has confirmed this deletion 
/ insertion mechanism (data not shown). Finally five single point missense mutations were 
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identified (patients 21, 22, 23 and 24). In two heterozygous patients the second obligatory GT 
mutation remains to be determined. 
 
Flow cytometry analysis of mutant complexes expressed in COS-7 cells 
Seven missense mutations not previously reported in the literature have been further 
studied by expressing the mutant complexes in COS-7 cells to assess their role in the GT 
phenotype. Cell surface expression of the mutant complexes was assessed by flow cytometry 
using Moabs SZ22 to αIIb, SZ 21 to β3 or P2 to the αIIbβ3 complex (see Figure 1). αIIb 
p.S926L (patient 16) and p.V903F (patients 6 and 15) and β3 p.C38Y (patient 21), p.M118R 
(patient 22), p.G221D and p.K253M (patient 24) substitutions prevented normal complex 
expression, mimicking the type I GT phenotype observed for the patients. For the αIIb 
p.S926L (patient 16) and β3 p.G221D and p.K253M (patient 24) mutants the percentage of 
positive cells expressing β3 was slightly higher than in other mutants tested (see Figure 1). 
This low level expression could be correlated to the 10 % of β3 expression at the surface of 
the patients’ platelets (see Supp Table S1). 
Surprisingly, the αIIb p.Q595H substitution identified in a GT type I patient did not affect 
the expression of the mutant complex which is similar to that obtained with the wild type 
form.  
As control, untransfected cells did not significantly bind any of the Moabs tested and 
irrelevant mouse IgG gave less than 1 % of positive cells whatever the transfectant tested. 
 
In silico analyses of mRNA processing for missense allelic variations and for the intronic 
deletion c.1125+3_1125+6del 
Some exonic single point mutations can alter normal processing of the mRNA and lead to 
the synthesis of an aberrant mRNA, associated or not with its degradation. Genscan, 
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13
NNSPLICE 0.9 and ESEFinder web servers were used to predict the effect of the missense 
mutations responsible for the substitutions that have been tested in flow cytometry. From this 
panel, the c.1878G>C responsible for the p.Q595H substitution was the unique variation 
predicted to modify normal splicing and to affect ESE binding sites. Splice site prediction by 
NNSPLICE 0.9 cannot identify the normal donor splice site of intron 18 in the mutant. 
Genscan analysis did not predict splice anomalies, but scores were lowered for both exons 18 
(0.987 to 0.791) and 19 (0.995 to 0,849) implying a probability of correct splicing of 75 % 
instead of 99 % for the normal sequence. Furthermore ESEFinder shows mutation 1878G>C 
to increase the score of an SF2/ASF binding site from 2.67 to 3.28 and to create a new one 
with a score of 2.50 (threshold 1.95). Finally an SRp55 binding site that presents a high score 
(4.33 - threshold 2.67) encompassing the normal splice site is also created. 
In the β3 gene, the homozygous 4 bp deletion c.1125+3_1125+6del (patient 25) was the 
single intronic mutation identified which does not directly affect a splice site. However 
Genscan analysis predicts the use of a cryptic donor splice site located 70 bp downstream the 
normal one. If this transcript is not degraded, this would lead to an in frame introduction of 23 
amino-acids between β3 β-I and hybrid domains. ESEFinder shows no modifications but 
NNSPLICE 0.9 suggests the contiguous donor splice site would be ignored in the mutant.  
 
Western-blot analysis of the p.C38Y β3 mutation effect on the complex expression.  
All the β3 mutants tested strongly affect complex expression (Figure 1) but the p.C38Y 
substitution also strongly and specifically affects that of β3 when tested with anti-β3 Moab 
SZ21. To understand this specific effect, synthesis of the Y38β3 form of the complex in the 
transfected cells was analyzed by using a Western-blot technique with Moabs SZ22 to αIIb 
and SZ21, XIIF9 and AP3 to β3 (see Figure 2). SZ22 showed that αIIb is clearly detectable in 
the lysate of the wild type αIIbβ3 transfectant (lane c) as in the control platelet lysate (lane a). 
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14
For the αIIb-Y38β3 mutant transfectant, only a band of slightly greater relative mobility 
which might correspond to a degradation product of αIIb was detected (lane d). Moab XIIF9 
revealed the presence of the Y38β3 mutant in the αIIb-Y38β3 transfectant (lane d). However, 
this mutant glycoprotein presents a lower relative mobility when compared to the wild type 
forms detected in lysates from platelets or wild type αIIbβ3 transfectant (lane c). Both SZ21 
and AP3 failed to react with the Y38β3 mutant (lanes d) but reacted with normal β3 expressed 
in platelet and wild type αIIbβ3 transfectant (lanes a and c respectively). XIIF9 and AP3 but 
not SZ21 reacted with the endogenous β3 subunit of the vitronectin receptor expressed in 
Cos-7 cells as shown by the faint band detected in non transfectant cells (lane b). These 
results suggested that the p.C38Y mutation should impair the complex formation, or at least 
its normal processing, as no αIIb of normal mobility could be detected.  
 
Role of the Lys253 of the β−I domain of β3 in the interaction with the αIIb 
β-propeller 
To understand precisely the impact of the p.K253M mutation, we have analyzed the 
interface between αIIb (residues 1-452) and β3 (residues 109-352) subunits using the protein 
structures obtained by the group of Springer (PDB code 2VDL [Springer et al., 2008]). From 
a simple visualization, the side chain of the β3 K253 protrudes from the β−I domain toward 
the αIIb beta-propeller surface and makes contact with different residues of the αIIb subunit 
(see Figure 3A). Table 3 summarizes the different results concerning the estimations of the 
direct electrostatic and desolvation interaction free energy between the αIIb and β3 chains. 
Interestingly, K253 has a key role in terms of binding free energy with the most negative 
contribution (-5.5 kcal/mol) and also in terms of electrostatics (-9.7 kcal/mol). Inversely, 
desolvation free energy is high (+4.1 kcal/mol). The desolvation of charged and polar amino 
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acid is unfavorable from an energy point of view. This penalty of desolvation is greatly 
compensated by Coulomb interactions and by the hydrogen bonds which are formed in the 
complex.  
Analysis of important interactions of by K253 underlines its weight in the interaction as it 
has the 1st (-6.7 kcal/mol with D232 of αIIb), the 6th (-2.0 kcal/mol with F231) and the 13th (-
0.8 kcal/mol with P238) most negative interactions of the interface. One interaction with 
W262 is slightly unfavorable. Concerning free energy, the same observations are made, with 
two strong interactions with D232 (-5.5 kcal/mol) and F231 (-1.2 kcal/mol). One unfavorable 
interaction is observed again with W262. These results highlight the significance of this 
residue, the most important in terms of electrostatic and free energy computation.  
A structural model of M253 mutant was constructed. Regarding the whole αIIb and β3 
interface, the substitution provokes a striking loss of electrostatic energy (+9.1 kcal/mol) but a 
gain in desolvatation free energy (-5.72 kcal/mol) that cannot counter-balance the decrease of 
electrostatic energy. As shown in Table 3, the diminution of the length of the side-chains and 
the change from a charged polar amino acid to a hydrophobic amino acid has a deep impact. 
Residue 253 has no more (negative) interaction with either D232 or F231, or P238. Only a 
single interaction with W262 is conserved (see Figure 3B).  
From a visual point of view, the decrease of electrostatic energy between K253 (see 
Figure 3C) and M253 (see Figure 3D) is striking. Overall, the most important electrostatic 
energy implicated in the interaction becomes negligible. All these contacts are lost in presence 
of the methionine, except for W262 that only preserves an electrostatic link. These results 
indicate that it is rather the loss of K253 lost than the presence of the methionine which is 
responsible for the defect of complex expression. 
 
DISCUSSION 
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The aim of the study was to identify mutations responsible for GT platelet phenotype. 
SDS-PAGE, western-blot and flow cytometry analyses carried out on patients’ platelets 
confirmed GT clinical diagnosis. Twenty-nine mutations were identified in both αIIb and β3 
genes. Most of these mutations (47 %) correspond to missense mutations but nonsense, 
insertion, deletion, and single point mutations affecting splice sites were also found.  
Mutations previously reported in the literature (see tables 1 and 2) have not been further 
studied in-vitro for their involvement in GT. It can be noted that their presence in the patients 
studied herein and in one or more additional unrelated patients would confirm their role in GT 
phenotype. New mutations directly affecting splice sites, creating nonsense codon or insertion 
/ deletion associated with frame shift anomaly were considered as known cause of GT. The 
pathological effects of new allelic variations responsible for missense substitutions and one 
new allelic variation leading to a splicing anomaly are discussed below. 
The substitutions p.V903F (patient 6 and propositus 15) and p.S926L (patient 16) affect 
the extra-cellular N-terminal part of the αIIb β-subunit that composes the calf-2 domain (see 
Figure 4). In both cases they prevent αIIbβ3 complex expression at the Cos-7 cell surface. 
They are predicted to impair the correct folding of the Calf-2 domain as the amino-acids V903 
and S926 are located in its core (see Figure 4). To estimate their structural importance, the 
human αIIb primary sequence has been aligned with several corresponding integrin sequences 
- marsupial, fish, amphibian, prochordates and insect (Supp Figure S1A). These sequences 
share at least 45 % of identity with the human αIIb (Psi-blast data from 
http://www.ncbi.nlm.nih.gov/BLAST) and only 17 % of these residues are conserved through 
all the seven organisms tested. It is noteworthy that V903 and S926 belong to these few 
amino-acids, indicating that their conservation could be linked to a strong structural 
evolutionary constraint. Furthermore, their poor conservation in other human integrin α-
subunits (data not shown) reinforces their α-IIb specificity.  
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The missense mutation c.1878G>C (patient 10), contiguous with the donor splice site of 
intron 18, was predicted to be responsible for a p.Q595H substitution in αIIb. However this 
p.Q595H mutation identified in a type I GT patient does not prevent the expression of the 
mutant complex at the surface of transfected Cos-7 cells. Study of the patient’s platelet 
mRNA revealed full normal β3 mRNA synthesis but αIIb mRNA remained undetectable. A 
splicing anomaly can lead to mRNA decay and explain the lack of detection of the mRNA 
coding for αIIb in patient 10. In silico splicing testing by using the Genscan and NNSPLICE 
0.9 web servers effectively predicted splicing anomalies. Similarly Jayo and coworkers [Jayo 
et al., 2006] reported that the αIIb c.2829C>T mutation (exon 27) predicted to induce a 
p.L912P substitution, partially leads to exon 28 skipping. The authors pointed out that rather 
than the disruption of an ESE site, the aberrant mRNA processing would result from the 
strengthening of the SR protein SC35 binding score by 0.65 units (ESEFinder analysis). 
Interestingly the ESEFinder web server predicted the mutation c.1878G>C to increase the 
score by 0.61 of an existing SF2/ASF binding site and to create two new binding sites for 
SF2/ASF and SRp55 factors with significant high scores (respectively 2.5 and 4.33). It can 
therefore be hypothesized that the 1878G>C mutation alters the normal splice factor pattern 
necessary to accurately splice intron 18. This was confirmed by a minigene study that showed 
the c.1878G>C alteration to provoke exon 18 skipping during mRNA splicing (data not 
shown). 
In the β3 gene, the homozygous 4 bp deletion c.1125+3_1125+6del (patient 25) was the 
single intronic mutation identified that does not directly affect a splice site but its contiguous 
intronic sequence. Genscan analysis predict an altered splicing that correlates with the partial 
loss of a sequence necessary to hybridize a small nuclear ribonucleoprotein involved in the 
splicing process [Wang and Cooper, 2007]. 
Page 17 of 44
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
in
se
rm
-0
04
48
02
4,
 v
er
sio
n 
1 
- 1
8 
Ja
n 
20
10
For Peer Review
   
   
 
18
The mutation c.191G>A (patient 21) responsible for a p.C38Y substitution, is located in 
the PSI domain of the β3. Transient co-transfection of the β3 mutated cDNA and with normal 
αIIb cDNA showed the mutation to reproduce a GT type I phenotype as no complex was 
detected on the cell surface by any of the anti-αIIbβ3 Moabs tested herein and including 
testing with a panel to β3 (XIIF9, AP3 and Y2-51, data not shown). Computational analysis 
(Genscan, ESEFinder and NNSPLICE 0.9) indicated that the c.191G>A mutation would not 
induce splicing modification of the pre-mRNA. However, western-blot analyses showed that 
αIIb and the mutated β3 were synthesized in transfected COS cells. The mutated Y38 β3 
presents a lower relative mobility than the wild type form which could result from structural 
modifications induced by the C16 – C38 disulfide bond disruption. A similar observation has 
been reported by Valentin and co-workers [Valentin et al., 1995], who have shown that 
alanine substitution of C38 lowered the relative mobility of β3 expressed in COS cells. The 
structural modification of the PSI domain induced by the p.C38Y mutation was evidenced by 
the lack of reactivity of Moabs AP3 and SZ21 whose epitopes are respectively located in 
amino-acids stretches 49-98 [Peterson et al., 2003] and 28-35 [Honda et al., 1995]. So the 
structural anomaly of the PSI domain impairs the complex association and / or its post-
translational maturation leading to its retention inside the cell. 
The missense mutations p.M118R, p.G221D and p.K253M are located in the β-I domain of 
β3 and are responsible for Type I GT. M118 and G221 are highly conserved in most integrin 
β subunits (data not Shown), and through invertebrates to vertebrates (see Supp Figure S1B). 
Most of the β-I domain mutations previously described, are responsible for Variant [Bajt et 
al., 1992; D'Andrea et al., 2002; D'Andrea et al., 2008; Lanza et al., 1992; Loftus et al., 1990] 
or type II GT [Jackson et al., 1998; Morel-Kopp et al., 2002; Nair et al., 2004; Tadokoro et 
al., 2002; Ward et al., 2000]. For comparison, Figure 5 locates the mutated amino-acids in the 
primary sequence (panel A) and in the β-I domain structure (panel B). Whatever the variant or 
Page 18 of 44
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
in
se
rm
-0
04
48
02
4,
 v
er
sio
n 
1 
- 1
8 
Ja
n 
20
10
For Peer Review
   
   
 
19
type II GT phenotype, the mutated complexes are located completely or partially at the 
surface of the β-I domain, and some of them (see Figure 5B, underlined amino-acids) present 
significant electrostatic or / and free energies interactions with the β-propeller (data not 
shown). Variant mutations concern the MIDAS or SyMBS sites [Zhu et al., 2008] directly 
affecting amino-acids involved in metal coordination (p.D119Y, p.S123P) or their very 
nearby environment (p.R217W or Q) (see Figure 5A). Both variant and GT Type II mutations 
support at least a 10 % expression of αIIbβ3 at the platelet surface. This contrasts with the 
failure to detect the β3-R118 and -D221 forms of the complex. Both the p.M118R and the 
p.G221D mutations, located inside the β-I domain, should deeply alter its proper folding, 
preventing complex expression at the platelet surface. Due to the nature of the amino-acid 
involved, these mutations induce important changes of steric hindrance and charge. However, 
in one case, the mutation p.L117W which affects a 100 % buried amino-acid still permits a 10 
% expression of αIIbβ3 at the platelet surface [Basani et al., 1997]. We could hypothesize that 
the characteristics of these residues, both hydrophobic and aliphatic, could explain this 
behavior. In contrast the p.G221D mutation, changes of volume and charge of the side-chains 
has a too deep impact. Similarly, such a steric hindrance change could explain the type I 
phenotype induced by the p.M124V mutation [Gonzalez-Manchon et al., 2004], as the M124 
side chain pointed inward the β-I domain. 
Unlike for M118 and G221, K253 is not conserved in other integrin β subunits and if it is 
present in β3 from fish to primates it is replaced by an arginine in amphibian and absent from 
invertebrate integrins (see Supp Figure S1B). However the p.K253M substitution results in 
type I GT. The 3-dimensional structure of the αIIbβ3 headpiece revealed that the side chain of 
K253 protrudes from the β-I domain toward a pocket at the surface of the αIIb β-propeller 
(see Figure 3A and 5B). Analyses of electrostatic, desolvation and free energies revealed that 
K253 is one of the most important amino-acids involved in the β-I domain interaction with 
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the β-propeller of αIIb. Furthermore, a mutant model of the αIIbβ3 headpiece shows that the 
p.K253M substitution does not introduce steric and energy clashes but only suppresses 
important contacts with the αIIb β-propeller. So, the p.K253M mutation revealed K253 as a 
key amino-acid for the association of the β-I domain with the β-propeller. The last mutation 
reported so far of the β-I domain that leads to type I GT was a substitution of the 
I325-P326-G327 sequence by a methionine. This mutation impairs the αIIbβ3 association 
[Morel-Kopp et al., 1997]. However, the mutated amino-acids locate between the α6 helix 
and the β7 sheet and do not directly face the αIIb β-propeller surface (see Figure 5B). 
Furthermore the I325-P326-G327 sequence does not seem to have significant if any, 
interaction with the β-propeller as indicated by free and electrostatic energy analysis (data not 
shown). It might indirectly impair the interaction(s) of the α5 and / or α6 helix with the 
β-propeller. The last four mutations described, p.K137Q [Peterson et al., 2008], p.T140I 
(HPA-16bw) [Jallu et al., 2002], p.R143Q (HPA-4) [Wang et al., 1992] and p.T195N (HPA-
17bw) [Stafford et al., 2008] only lead to allelic variants involved in alloimmune 
thrombocytopenia that are not related to GT phenotype. All these amino-acids locate at the 
surface of the β-I domain with their side chains directed outside.  
 
In conclusion, we have identified 29 mutations in a panel of 24 GT patients and 2 GT 
carriers. Seventeen of these mutations have not been described so far. We have confirmed by 
in vitro studies that the missense mutations identified impaired normal expression of the 
mutant complex (except for one case). Nonsense and splice site mutations were considered to 
be related to the GT phenotype. This study emphasizes the high allelic heterogeneity of both 
the αIIb and β3 genes involved in GT phenotype. Finally the GT variant p.K253M of β3 
unveiled the key role of K253 in the β-propeller / β-I association of the αIIbβ3 headpiece. 
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Figure legends : 
 
Figure 1 : Flow cytometry analysis of the expression of the mutant forms of αIIbβ3. 
Transiently transfected COS-7 cells expressing the wild type (WT) or the following mutants 
of αIIbβ3, p.S926L, p.Q595H, p.V903F (αIIb) and p.C38Y, p.M118R, p.G221D, p.K253 
(β3) were tested in flow cytometry by using Moabs SZ22 (hatched bar), SZ21 (dot bar) and 
P2 (white bar) or irrelevant mouse IgG (black bar). As control, untransfected cells (NT) were 
also tested. Following Moab incubation, bound IgGs were detected by using a polyclonal goat 
anti-mouse IgG conjugated to FITC. Washed cells were analyzed on an Epic-XML flow 
cytometer. Except for the αIIb p.Q595H one, all mutants showed a markedly decreased 
expression of the complex when compared to the wild type. Results represent the mean ± SD 
of 3 experiments. 
 
Figure 2 : Western blot analysis of the Y38 β3 form of the αIIbβ3 complex expressed 
in COS-7 cells. SDS lysates from normal platelets (lane a), non-transfected COS-7 cells (lane 
b), or COS-7 cells expressing the wild-type (lane c) or the Y38 β3 (lane d) forms of the 
complex were subjected to SDS-polyacrylamide gel electrophoresis under non reduced 
conditions and transferred to nitrocellulose membrane. Following incubation with Moabs 
SZ22, XIIF9, SZ21 and AP3, membrane bound IgGs were revealed by using anti-mouse IgG 
conjugated to peroxidase and the enhanced chemiluminescence detection technique.  
 
Figure 3 : Location and modeling of the electrostatic effect of the p.K253M 
substitution. (A) and (B) Ribbon diagram of the αIIb β-propeller (in blue) and β3 βI (in red) 
complexed domains. For the βI domain, The residue 253 is shown in green with (A) a lysine 
and (B) a methionine, while for β-propeller partners the P228 is shown in yellow, the F231 in 
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grey, the W262 in pink and the D232 in orange. (C) and (D) Electrostatics visualization of the 
single point mutation p.K253M with (C) wild K253 β3 and (D) mutated M253 β3 subunits. 
The visualizations are done using PyMol software (http://www.pymol.org). 
 
Figure 4 : Localization of the V903 and S926 on a ribbon diagram of αIIb. This αIIb 
cartoon shows the internal location of the V903 and S926 side chains (orange, ball and stick 
representation) in the calf-2 composed by the N-terminal part of the β-subunit of αIIb (blue) 
and the C-terminal part of the α-subunit (yellow and red respectively for β-sheet and α-helix). 
This ribbon diagram was obtained from the resolved structure of αIIb (PDB code 3FCS) using 
the Swiss-PdbViewer software (version 4.0.1). 
 
Figure 5 : Localization of the allelic variants of the β-I domain of β3. Residues 
identified in this study and from the literature as involved in GT or neonatal alloimmune 
thrombocytopenia and that locate in the β-I domain of β3 are reported on its primary sequence 
(panel A) and a ribbon diagrams showing the β-I domain and a partial view of the β-propeller 
of αIIb (panel B). Allelic variants of residues highlighted in magenta, blue, green are 
respectively responsible for variant, II and I GT phenotypes or yellow for those concerning 
alloimmunisation. The GT type induced by the allelic variant of the H192 (grey) is not 
reported [Peretz et al., 2006]. Amino-acids identified by the energy analyze as in contact with 
the αIIb β-propeller are underlined. The primary sequence (panel A) identifies the secondary 
structures [Xiao et al., 2004] and amino-acids responsible for MIDAS (), ADMIDAS () 
and SyMBS () sites [Springer et al., 2008]. As known, variant GT mutations GT specifically 
affect metal ion binding sites but other mutants concern residues evenly distributed along the 
primary sequence. Boxed residues have been identified in this study. The ribbon diagram 
(panel B) was obtained from the resolved structure of αIIb (PDB file 2VDL) using the Swiss-
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PdbViewer software (version 4.0.1). α-helix (red) and β-sheet (yellow) are shown. All 
residues whose mutants are involved in type II GT lay on the β-I surface except for the L117, 
some of them (underlined amino-acids) directly contacting the β-propeller. The Met 118 and 
Gly 221 locate inside the β-I domain and the Lys 253 points out to the β-propeller surface 
however their identified allelic variants completely prevent the αIIbβ3 complex expression at 
the platelet surface. 
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Table 1 : αIIb mutations identified by genomic analysisa 
N° Proband GTb Ex/IVSc Sequence alterationd Statuse Restriction enzyme Predicted HGVSf Predicted Classicalg Accession numberh 
1 CabGT-1 I Ex 4 c.531T>A Hom. Hga I p.C177* p.C146* ss131010618 
Ex 10 c.917dupA Het. Alw I p.R307Efs*22 p.R276E + FSk ss131007603 2 CabGT-2 I 
Ex19 c.1912dup T Het. No enzyme p.C639Mfs*22 p.C608M + FSk,l ss 131007606 
Ex 13  c.1214T>C Het. Sfc I p.I405T p.I374Tl ss 131007609 3 CabGT-3 I 
IVS14 c.1442-13_1442-1del Het. Hph I Splicei Splice ss 131007612 
4 CabGT-4 I (carw) IVS14 c.1442-13_1442-1del Het. Hph I Splice Splice ss 131007612 
IVS14 c.1442-13_1442-1del Het. Hph I Splice Splice ss 131007612 5 CabGT-5 I 
  NIj         
Ex 14 c.1413C>G Het. Dde I p.Y471* p.Y440*m ss 131007615 6 CabGT-6 I 
Ex 27 c.2800G>T Het. Mae III / Tsp45 I p.V934F p.V903F ss 131007617 
Ex 16 c.1563T>A Het. No enzyme p.C521* p.C490* ss 131007620 7 CabGT-7 I 
  NI         
8 CabGT-8 NCx Ex 17 c.1672C>T Hom. Mse I p.Q558* p.Q527* ss 131007623 
9 CabGT-9 I IVS18 c.1879-2A>G Hom. Xba I Splice Splice ss 131007625 
10 CabGT-10 I Ex 18 c.1878G>C Hom. Hpy CH IV p.Q626H / Splice p.Q595H / Splice ss 131007628 
11 CabGT-11 I Ex 18 c.1787T>C Hom. No enzyme p.I596T p.I565Tn ss 131008441 
Ex 21 c.2113T>C Het. Fok I p.C705R p.C674Rl,o,p ss 131007632 12 CabGT-12 II 
IVS29 c.3060+2T>C Het. Hph I p.V982_K1020del  p.V951_K989delq  ss 131007634 
13 CabGT-13 I Ex 23 c.2333A>C Hom. Bsr I / TspR I p.Q778P p.Q747Pr ss 131007637 
14 CabGT-14 I Ex 27 c.2748_2757del Hom. Rsa I p.T917Sfs181 p.T886S + FS ss 131007639 
15 CabGT-15 I (car) Ex 27 c.2800G>T Het. Mae III / Tsp45 I p.V934F p.V903F ss 131007617 
16 CabGT-16 I Ex 28 c.2870C>T Hom. Hpy CH4 V p.S957L p.S926L ss 131007642 
Ex 28 c.2929C>T Het. Ava I p.R977* p.R946*l,s,t ss 131007644 17 CabGT-17 II 
 NI      
Ex 29 c.2944G>A Het. Bst NI p.V982M p.V951Mu,v ss 131007647 
Ex 29 c.2965G>A Het. Nci I p.A989T p.A958Tu,v ss 131007649 18 CabGT-18 NC 
  NI         
a cDNA ITGA2B GenBank accession number NM_000419.3 
b GT : Glanzmann type 
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c Ex : Exon ; IVS : intronic sequence  
d Nomenclature according to HGVS : +1 corresponds to the A of ATG translation initiation codon 
e Status : Het. : heterozygous; Hom. : Homozygous 
f Predicted effect, nomenclature according to HGVS : +1 corresponds to the initiating Met (signal peptide included) 
g Predicted effect, classical nomenclature : +1 corresponds to the first amino acid of the mature αIIb 
h
 NCBI dSNP accession number 
i Splice defect based upon modeling with GENSCAN / NNSPLICE and ESEFinder 
j NI : 2nd mutation not Identified  
k FS : Frame shift 
References : l D'Andrea et al., 2002 [D'Andrea et al., 2002]; m Scott et al., 1998 [Scott et al., 1998]; n Ruan et al., 1998 [Ruan et al., 1998]; o Gonzalez-
Manchon et al., 1999 [Gonzalez-Manchon et al., 1999]; p Mitchell et al., 2003 [Mitchell et al., 2003]; q French et al., 1997 [French and Coller, 1997]; 
r
 Tadokoro et al., 1998 [Tadokoro et al., 1998]; s Basani et al., 2000 [Basani et al., 2000]; t Peretz et al., 2006 [Peretz et al., 2006]; u Nurden et al., 2004 
[Nurden et al., 2004] 
v V951M is responsible for GT but not A958T [Nurden et al., 2004] 
w
 Car : carrier 
x
 NC : Not communicated 
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Table 2 : β3 mutations identified by genomic analysis
a
 
N° Proband GT
b
 Ex/IVS
c
 Sequence alteration
d
 Status
e
 Restriction enzyme Predicted HGVS
f
 Predicted Classical
g
 Accession number
h
 
19 CabGT-19 NC
j
 IVS2 c.166-2A>G Hom. Apa I Splice
i
 Splice ss 131007652 
20 CabGT-20 I Ex 2 c.100C>T Hom. Hpy CH4 IV p.R34* p.R8*
l
 ss 131007655 
Ex 3 c.191G>A Het. Tsp 45I p.C64Y p.C38Y ss 131007657 
21 CabGT-21 I 
  NI
k
        
22 CabGT-22 I Ex 4 c.431T>G Hom. Bsm F1 p.M144R p.M118R ss 131007660 
23 CabGT-23 II Ex 5 c.665 T>C Hom. Acy I p.L222P p.L196P
m
 ss 131007662 
Ex 5 c.740 G>A Het. Fok I p.G247D p.G221D ss 131007665 
24 CabGT-24 I 
Ex 6 c.836 A>T Het. Fat I p.K279M p.K253M ss 131007667 
IVS8 c.1125+3_1125+6del Het. No enzyme Splice Splice ss 131007670 
25 CabGT-25 NC 
 NI      
Ex 9 c.1143C>A Het. Taq I ss 131007672 
26 CabGT-26 I 
Ex 9 c.1260G>A Het. Hph I 
p.K376_T420del p.K350_T394del
n
 
ss 131007674 
a 
cDNA ITGB3 GenBank accession number NM_000212.2 
b
 GT : Glanzmann type I or II (< 5% or 10 – 25 % of normal platelet αIIbβ3[Caen, 1989]). See Supp_mat tableS1 for detailed data.
 
c 
Ex : Exon ; IVS : intronic sequence  
d 
Nomenclature according to HGVS : +1 corresponds to the A of ATG translation initiation codon 
e
 Status : Het. : heterozygous; Hom. : Homozygous
  
f 
Nomenclature according to HGVS : +1 corresponds to the initiating Met (signal peptide included) 
g 
Classical nomenclature : +1 corresponds to the first amino acid of the mature β3 
h 
NCBI dSNP accession number
 
i
 Splice defect based upon modeling with GENSCAN, NNSPLICE and ESEFinder 
j
 NC : Not comunicated 
k 
NI : 2
nd
 mutation not Identified 
References : 
l
 Negrier et al., 1998 [Negrier et al., 1998]; 
m
 Nurden et al., 2002 [Nurden et al., 2002]; 
n 
Jin et al., 1996 [Jin et al., 1996] 
Page 32 of 44
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
in
se
rm
-0
04
48
02
4,
 v
er
sio
n 
1 
- 1
8 
Ja
n 
20
10
For Peer Review
Table 3 : Energetic effects of the Lys 253 Met substitution in the αIIb/ β3 interaction  
 
 Lys 253 Met 253 
Energy of : Rank Value (kcal/mol) 
αIIb 
contact rank 
Value 
(kcal/mol) 
αIIb 
contact 
Electrostatic (4r) Energy / -25.14 / / -16.08 / 
Desolvation Free Energy / -1.09 / / -6.81 / αIIbβ3 Interface 
Van der Waals (CHARMm19) / -4894.63 / / -4903.95 / 
Binding free energy 1st negative -5.541 / 12th negative -1.309 / 
Desolvation free energy 1st positive 4.124 / 6th negative -1.347 / Residue 
Electrostatic energy 1st negative -9.666 / / low / 
1st negative -6.715 D232 / / / 
6 th negative -2.076 F231 / / / 
13th negative -0.788 P228 / / / 
Electrostatic 
10th positive 0.670 W262 6th negative -0.935 W262 
1st negative -5.517 D232 / / / 
8th negative -1.166 F231 / / / 
Contact 
Free energy 
2th positive 2.057 W262 / / / 
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Figure 1 : Flow cytometry analysis of the expression of the mutant forms of αIIbβ3.  
235x165mm (96 x 96 DPI)  
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Figure 2 : Western blot analysis of the Y38 β3 form of the αIIbβ3 complex expressed in COS-7 cells. 
155x177mm (96 x 96 DPI)  
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CMYK color scale 
 
Figure 3 : Location and modeling of the electrostatic effect of the p.K253M substitution.  
193x158mm (96 x 96 DPI)  
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RGB color scale 
 
Figure 3 : Location and modeling of the electrostatic effect of the p.K253M substitution.  
193x158mm (96 x 96 DPI)  
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CYMK color scale 
 
Figure 4 : Localization of the V903 and S926 on a ribbon diagram of αIIb.  
135x115mm (96 x 96 DPI)  
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RGB color scale 
 
Figure 4 : Localization of the V903 and S926 on a ribbon diagram of αIIb.  
135x115mm (96 x 96 DPI)  
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CMYK color scale 
 
Figure 5 : Localization of the allelic variants of the β-I domain of β3.  
212x200mm (96 x 96 DPI)  
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RGB color scale 
 
Figure 5 : Localization of the allelic variants of the β-I domain of β3.  
212x200mm (96 x 96 DPI)  
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